Vivos Inc's Cash & cash equivalent grew by 62.06 % in the Q1 2026 sequentially, faster than Current Liabilities, this led to improvement in Vivos Inc's Quick Ratio to 17.59, above Vivos Inc average Quick Ratio.

Within Medical Equipment & Supplies industry 2 other companies have achieved higher Quick Ratio than Vivos Inc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 158 to 176.

Explain Quick Ratio?
How much Cash & cash equivalents RDGL�s has?
What are RDGL�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

RDGL Quick Ratio	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2	(Mar 31 2025) Q1
Y / Y Current Liabilities Change	24.44 %	7.27 %	130.85 %	-42.08 %	-52.9 %
Y / Y Cash & cash equivalent Change	-22.64 %	-29.56 %	80.77 %	54.29 %	105.06 %
Quick Ratio MRQ	17.59	16.85	19.54	27.57	28.29
RDGL's Total Ranking	# 176	# 158	# 136	# 75	# 85
Seq. Current Liabilities Change	55.28 %	-17.94 %	16.79 %	-16.38 %	33.86 %
Seq. Cash & cash equivalent Change	62.06 %	-29.23 %	-17.23 %	-18.51 %	47.57 %

Quick Ratio first quarter 2026 Company Ranking
Within:	No.
Medical Equipment & Supplies Industry	# 3
Healthcare Sector	# 71
Overall Market	# 176

Quick Ratio Statistics
High	Average	Low
28.83	6.66	0
(Mar 31 2023)		(Mar 31 2018)

Financial Statements
Vivos Inc's Current Liabilities	$ 0 Millions	Visit RDGL's Balance sheet
Vivos Inc's Cash & cash equivalent	$ 3 Millions	Visit RDGL's Balance sheet
Source of RDGL's Sales		Visit RDGL's Sales by Geography

Cumulative Vivos Inc's Quick Ratio

RDGL's Quick Ratio for the trailling 12 Months

RDGL Quick Ratio	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months
Y / Y Current Liabilities TTM Growth	6.77 %	-23.7 %	-27.65 %	-45.09 %	-18.9 %
Y / Y Cash & cash equivalent TTM Growth	6.26 %	43.56 %	70.3 %	41.71 %	33.86 %
Quick Ratio TTM	20.09	23.22	25.17	26.97	20.19
Total Ranking TTM	# 2216	# 2167	# 2252	# 1909	# 2387
Seq. Current Liabilities TTM Growth	6.76 %	1.53 %	18.41 %	-16.81 %	-23.71 %
Seq. Cash & cash equivalent TTM Growth	-7.63 %	-6.32 %	10.52 %	11.12 %	24.79 %

Quick ratio ranking by company, industry and sector >> Back to RDGL Financial Strength Comparisons >> Go to Compare RDGL Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q1 2026 to $0.14 millions, cumulative Quick Ratio decreased to 20.09 above the RDGL average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Equipment & Supplies industry 153 other companies have achieved higher Quick Ratio than Vivos Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from 2167 to 2216.

Explain Quick Ratio?
How much Cash & cash equivalents RDGL�s has?
What are RDGL�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Equipment & Supplies Industry	# 154
Healthcare Sector	# 736
Within the Market	# 2216

trailing twelve months Quick Ratio Statistics
High	Average	Low
26.97	7.8	0
(Jun 30 2025)		(Dec 31 2018)

Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Medical Equipment & Supplies Industry	Quick Ratio	Mar 31 2026 MRQ Cash & cash equivalent	Mar 31 2026 MRQ Current Liabilities
FAMILY OFFICE OF AMERICA, INC.	25.05	$ 0.343 Millions	$ 0.014 Millions
Utah Medical Products Inc	24.94	$ 87.406 Millions	$ 3.505 Millions
Microbot Medical Inc	24.00	$ 73.506 Millions	$ 3.063 Millions
Beta Bionics Inc	22.10	$ 199.520 Millions	$ 9.030 Millions
Vivos Inc	17.59	$ 2.526 Millions	$ 0.144 Millions
Bone Biologics Corporation	14.66	$ 4.530 Millions	$ 0.309 Millions
Conexeu Sciences Inc	13.87	$ 7.302 Millions	$ 0.526 Millions
Safe Pro Group Inc	13.36	$ 14.802 Millions	$ 1.108 Millions
Envveno Medical Corporation	11.63	$ 24.930 Millions	$ 2.143 Millions
Lemaitre Vascular Inc	11.01	$ 367.233 Millions	$ 33.369 Millions
Carlsmed Inc	9.99	$ 97.016 Millions	$ 9.715 Millions
Ceribell Inc	9.44	$ 141.184 Millions	$ 14.955 Millions
Streamex Corp	9.27	$ 30.625 Millions	$ 3.302 Millions
Perspective Therapeutics Inc	8.60	$ 270.929 Millions	$ 31.486 Millions
Delcath Systems Inc	8.42	$ 89.299 Millions	$ 10.606 Millions
Rxsight Inc	7.96	$ 217.880 Millions	$ 27.376 Millions
EBR Systems, Inc.	7.63	$ 54.194 Millions	$ 7.106 Millions
Cvrx inc	7.62	$ 72.303 Millions	$ 9.486 Millions
Talkspace Inc	7.23	$ 84.212 Millions	$ 11.655 Millions
Pulse Biosciences Inc	6.97	$ 68.319 Millions	$ 9.796 Millions
Orchestra Biomed Holdings Inc	6.89	$ 94.400 Millions	$ 13.692 Millions
Beyond Air Inc	6.59	$ 28.984 Millions	$ 4.395 Millions
Alpha Pro Tech Ltd	6.45	$ 16.883 Millions	$ 2.619 Millions
Mobia Medical Inc	5.72	$ 55.725 Millions	$ 9.750 Millions
Sharps Technology Inc	5.55	$ 12.321 Millions	$ 2.219 Millions
Omada Health Inc	5.38	$ 211.765 Millions	$ 39.327 Millions
Transmedics Group Inc	5.02	$ 461.739 Millions	$ 91.920 Millions
Heartflow Inc	5.00	$ 158.316 Millions	$ 31.636 Millions
Irhythm Holdings Inc	4.96	$ 549.620 Millions	$ 110.901 Millions
Tactile Systems Technology Inc	4.86	$ 74.993 Millions	$ 15.442 Millions

Date modified: 2026-09-08T15:11:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.